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Adoptive T cell therapy can mediate durable regression
of cancer [1]. While pre-existing anti-tumor responses
can only be cultured from a minority of cancer patients
[2], T cells specific for a wide variety of tumor antigens
can be generated by stimulation of naive precursor cells
with tumor antigen [3]. This culture process relies on
autologous antigen presenting cells and feeder cells,
which are complex biologics that must be generated for
each individual patient [4], significantly increasing the
cost and complexity of adoptive immunotherapy.
To quickly generate large numbers of functional tumor-
specific T cells from naïve T cell precursors, we developed
a T cell Enrichment+Expansion strategy using paramag-
netic, nanoscale artificial Antigen Presenting Cells (nano-
aAPC), which are capable of enriching rare tumor-specific
T cells in a magnetic column and activating them. We
generated up to 150,000 total Trp2-specific cells in only
one week from 10 million polyclonal CD8 lymphocytes
containing approximately 10 precursor cells [5]. Similar
results were obtained for other tumor and model antigens,
including the human tumor antigens A2-NY-ESO1 and
A2-MART1. We further demonstrate that removing irre-
levant bystander cells by enrichment confers a significant
survival and proliferation advantage to tumor-specific
T cells both during in vitro culture and after adoptive
transfer in vivo. Streamlining the generation of large num-
bers of high-frequency tumor-specific T cells in a cost
effective, reproducible fashion through Enrichment
+Expansion could be a powerful addition to autologous
tumor immunotherapy protocols.
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